+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 80Years
All Genders
ID06650566

Phase III Study of LM-299 Injection to Evaluate Safety, Tolerability, and Effectiveness in Adults With Advanced Solid Tumors

Led by LaNova Medicines Limited · Updated on 2025-05-02

108

Participants Needed

6

Research Sites

30 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating LM-299 in patients with advanced solid tumors to understand its safety, tolerability, and antitumor activity. This Phase III open-label study aims to find the maximum tolerated or optimal biological dose of LM-299 and to assess its preliminary efficacy both as a single therapy and in combination with other anti-tumor treatments. The study is sponsored by LaNova Medicines Limited and includes adult patients with advanced malignant tumors who have limited treatment options. Participants receive LM-299 through intravenous drip either every two or three weeks. The study includes a Phase I dose escalation stage to determine the best dose, followed by a Phase II dose expansion stage to evaluate antitumor effects across various solid tumors. Different dose levels and backfill cohorts are studied without randomization or blinding. During the study, participants will undergo regular monitoring for dose-limiting toxicities, treatment-emergent adverse events, and heart function via echocardiography over approximately one year. Researchers will also assess tumor response rates and pharmacokinetic parameters for up to two years. Patients must provide tumor tissue samples and will be closely followed with evaluations including imaging and laboratory tests to monitor safety and treatment effects throughout the study period.

CONDITIONS

Brief Title

Study of LM-299 in Subjects Advanced Malignant Tumors

Research Team

A

Alex Yuan

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here